My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    PROTAC ABL binding moiety 2
    PROTAC ABL binding moiety 2

    Price:
    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V4535
    CAS #: 778277-37-5Purity ≥98%

    Description: PROTAC ABL binding moiety 2 is the GNF5 (an ABL inhibitor) moiety that binds to IAP (inhibitor of apoptosis protein) ligand via a linker to form SNIPER. Chromosomal translocation occurs in some cancer cells, which results in the expression of aberrant oncogenic fusion proteins that include BCR-ABL in chronic myelogenous leukemia (CML). Inhibitors of ABL tyrosine kinase, such as imatinib and dasatinib, exhibit remarkable therapeutic effects, although emergence of drug resistance hampers the therapy during long-term treatment. An alternative approach to treat CML is to downregulate the BCR-ABL protein. 

    References:  2017 Aug;108(8):1657-1666.


    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Related Products
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
     

    PROTAC ABL binding moiety 2

    Molecular Weight: 388.34
    Formula: C₁₉H₁₅F₃N₄O₂
    CAS No.: 778277-37-5
    SMILES: O=C(NC)C1=CC=CC(C2=NC=NC(NC3=CC=C(OC(F)(F)F)C=C3)=C2)=C1
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Technical InformationPROTAC ABL binding moiety 2


    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      •  
      • V1
      •  
      • C2
      •  
      • V2

    These protocols are for reference only. InvivoChem does not independently validate these methods.

    PROTAC ABL binding moiety 2


    SNIPER(ABL)‐39 shows potent protein knockdown activity. (a) Chemical structures of SNIPER(ABL) with different linker length. (b) Effect of linker length on the protein knockdown activity of the SNIPER(ABL).  (c) Dose response of the protein knockdown activity of SNIPER(ABL)‐39. (d) Binding affinities of SNIPER(ABL)‐39 to ABL and IAP.

    PROTAC ABL binding moiety 2

    SNIPER(ABL)‐39 inhibits proliferation of chronic myelogenous leukemia (CML) cells expressing native BCR‐ABL.  2017 Aug;108(8):1657-1666.

     PROTAC ABL binding moiety 2


    SNIPER(ABL) composed of various ABL inhibitors and IAP ligands. (a) Chemical structures of SNIPER(ABL). (b–e) The protein knockdown activities of imatinib‐conjugated (b), GNF5‐conjugated (c), HG‐7‐85‐01‐conjugated (d) and dasatinib‐conjugated SNIPER(ABL) (e) were evaluated. K562 cells were incubated with the indicated concentration of SNIPER or ligands mix (LM; indicated ABL inhibitor and IAP ligand) for 6 h. Numbers below the ABL panel represent BCR‐ABL/GAPDH or BCR‐ABL/β‐tubulin ratio normalized by vehicle control as 100. (f) List of SNIPER(ABL) compounds and their DC 50 values. The upper name represents the code number of the SNIPER(ABL) and the lower number shows the concentration of SNIPER(ABL) required to reduce BCR‐ABL protein by 50% (DC 50, nM).  2017 Aug;108(8):1657-1666.

     PROTAC ABL binding moiety 2


    Involvement of ubiquitin and IAP in SNIPER(ABL)‐39‐induced degradation of BCR‐ABL protein. (a) Turnover of BCR‐ABL proteins after SNIPER(ABL)‐39 treatment.  (b) Expression of Bcr‐Abl mRNA in K562 cells. (c) Effect of ubiquitin activating enzyme inhibitor MLN7243 on protein knockdown activity of SNIPER(ABL)‐39 in K562 cells. (d) Silencing of both cIAP1 and XIAP expression attenuates SNIPER(ABL)‐39‐dependent BCR‐ABL protein degradation.

    PROTAC ABL binding moiety 2

    SNIPER(ABL)‐39 inhibits the BCR‐ABL‐related signaling pathway. K562 cells were incubated with the indicated concentration of SNIPER(ABL)‐39 or dasatinib for 6 h. pBCR‐ABL, pSTAT5 and pCrkL stand for phosphorylated BCR‐ABL, STAT5 and CrkL, respectively.  2017 Aug;108(8):1657-1666.


    评论

      Home Prev Next Last page / pices

      发评论

      ×
      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      prompt
      Do you confirm the receipt?